MA43051A - Polythérapie pour le traitement d'une du vhc - Google Patents

Polythérapie pour le traitement d'une du vhc

Info

Publication number
MA43051A
MA43051A MA043051A MA43051A MA43051A MA 43051 A MA43051 A MA 43051A MA 043051 A MA043051 A MA 043051A MA 43051 A MA43051 A MA 43051A MA 43051 A MA43051 A MA 43051A
Authority
MA
Morocco
Prior art keywords
polytherapy
hcv
treatment
Prior art date
Application number
MA043051A
Other languages
English (en)
Inventor
David Apelian
Maria Gloria Beumont
Lieve Bijnens
Lawrence M Blatt
Sushmita Mukherjee Chanda
Dawei Chen
Milind Deshpande
John Fry
James Hui
Eugene JANS
Thomas Naoki Kakuda
Sivi Mahadevan
Roel Mertens
Avinash Phadke
Gaston Rafael Picchio
Dijck Alex Van
Remoortere Peter Van
Original Assignee
Achillion Pharmaceuticals Inc
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achillion Pharmaceuticals Inc, Janssen Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Publication of MA43051A publication Critical patent/MA43051A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
MA043051A 2015-09-29 2016-09-29 Polythérapie pour le traitement d'une du vhc MA43051A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562234408P 2015-09-29 2015-09-29
US201662299338P 2016-02-24 2016-02-24
US201662353708P 2016-06-23 2016-06-23
US201662365541P 2016-07-22 2016-07-22

Publications (1)

Publication Number Publication Date
MA43051A true MA43051A (fr) 2018-08-08

Family

ID=58406227

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043051A MA43051A (fr) 2015-09-29 2016-09-29 Polythérapie pour le traitement d'une du vhc

Country Status (11)

Country Link
US (2) US20170087174A1 (fr)
EP (1) EP3355991A1 (fr)
JP (1) JP2018529777A (fr)
KR (1) KR20180071276A (fr)
AU (1) AU2016331073A1 (fr)
BR (1) BR112018006206A2 (fr)
CA (1) CA3000415A1 (fr)
EA (1) EA201890818A1 (fr)
IL (1) IL258228A (fr)
MA (1) MA43051A (fr)
WO (1) WO2017059147A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10004719B1 (en) 2017-05-30 2018-06-26 Taigen Biotechnology Co., Ltd. Solid dispersion formulation
WO2020117715A1 (fr) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Analogues d'oligo-benzamide et leur utilisation dans le traitement du cancer
CA3203975A1 (fr) 2020-12-03 2022-06-09 Battelle Memorial Institute Compositions de nanoparticules polymeres et de nanostructures d'adn et procedes d'administration non virale
CA3216359A1 (fr) 2021-04-07 2022-10-13 Battelle Memorial Institute Technologies de conception, de construction, de test et d'apprentissage rapides pour identifier et utiliser des vecteurs non viraux
AU2024353375A1 (en) 2023-09-29 2026-04-09 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (fr) 2023-12-08 2025-06-12 Battelle Memorial Institute Utilisation de nanostructures d'origami d'adn pour systèmes de stockage de données basés sur des informations moléculaires

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2908313A1 (fr) * 2013-04-05 2014-10-09 Alios Biopharma, Inc. Traitement contre une infection par le virus de l'hepatite c utilisant une combinaison de composes
US9447132B2 (en) * 2013-04-12 2016-09-20 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
JP6366693B2 (ja) * 2013-05-16 2018-08-01 リボサイエンス・エルエルシー 4’−フルオロ−2’−メチル置換ヌクレオシド誘導体
WO2015110048A1 (fr) * 2014-01-23 2015-07-30 Sunshine Lake Pharma Co., Ltd. Composés cycliques pontés comme inhibiteurs du virus de l'hépatite c, compositions pharmaceutiques et utilisations correspondantes
SG11201703645XA (en) * 2014-11-10 2017-06-29 Glaxosmithkline Intellectual Property (No 2) Ltd Long acting pharmaceutical compositions for hepatitis c
KR20170081257A (ko) * 2014-11-10 2017-07-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 C형 간염에 대한 조합 장기 작용 조성물 및 방법
US20180021361A1 (en) * 2016-07-22 2018-01-25 Janssen Pharmaceuticals, Inc. Combination drug treatment for hepatitis c infection

Also Published As

Publication number Publication date
EA201890818A1 (ru) 2018-09-28
AU2016331073A1 (en) 2018-05-10
US20170087174A1 (en) 2017-03-30
EP3355991A1 (fr) 2018-08-08
JP2018529777A (ja) 2018-10-11
WO2017059147A1 (fr) 2017-04-06
KR20180071276A (ko) 2018-06-27
BR112018006206A2 (pt) 2018-10-09
CA3000415A1 (fr) 2017-04-06
IL258228A (en) 2018-05-31
US20170319572A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3641829A4 (fr) Promédicament d'interféron pour le traitement du cancer
EP3233878A4 (fr) Phosphoramidates pour le traitement du virus de l'hépatite b
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
MA45192A (fr) Traitement d'association
EP3474863A4 (fr) Phosphoramidates pour le traitement du virus de l'hépatite b
EP3347469A4 (fr) Méthodes et compositions pour le traitement du glaucome
EP3455205A4 (fr) Peptidomimétiques pour le traitement d'une infection à norovirus
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
EP3325963A4 (fr) Amélioration de l'estimation de globules
EP3322448A4 (fr) Nouvelle approche pour le traitement du cancer par immunomodulation
MA48637A (fr) Polythérapies pour le traitement du cancer
ME03070B (fr) Méthodes pour le traitement d'infections virales à filoviridae
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
EP3380200A4 (fr) Compositions pour le traitement des cheveux
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
MA45492A (fr) Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène
EP3380063A4 (fr) Compositions pour le traitement des cheveux
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension